We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.
An abstract is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)
References
1
1.Zhang, L, Chen, X. Comment on a meta-analysis of re-treatment for intravenous immunoglobulin-resistant Kawasaki disease. Cardiol Young2016, doi: 10.1017/S1047951116000172.CrossRefGoogle ScholarPubMed
2
2.Yang, X, Liu, G, Huang, Y, et al. A meta-analysis of re-treatment for intravenous immunoglobulin-resistant Kawasaki disease. Cardiol Young2015; 25: 1182–1190.CrossRefGoogle ScholarPubMed
3
3.Saneeymehri, S, Baker, K, So, T-Y. Overview of pharmacological treatment options for pediatric patients with refractory Kawasaki disease. J Pediatr Pharmacol Ther2015; 20: 163–177.Google ScholarPubMed
4
4.Patel, RM, Shulman, ST. Kawasaki disease: a comprehensive review of treatment options. J Clin Pharm Ther2015; 40: 620–625.CrossRefGoogle ScholarPubMed
5
5.Miura, M, Ohki, H, Yoshiba, S, et al. Adverse effects of methylprednisolone pulse therapy in refractory Kawasaki disease. Arch Dis Child2005; 90: 1096–1097.CrossRefGoogle ScholarPubMed
6
6.Miura, M, Kohno, K, Ohki, H, Yoshiba, S, Sugaya, A, Satoh, M. Effects of methylprednisolone pulse on cytokine levels in Kawasaki disease patients unresponsive to intravenous immunoglobulin. Eur J Pediatr2008; 167: 1119–1123.CrossRefGoogle ScholarPubMed